Cargando…

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis

The clinical pharmacology of elagolix was extensively evaluated in clinical studies in healthy subjects and in women with endometriosis. Elagolix pharmacokinetics (PK) show significant population variability, however they are minimally affected by patients’ baseline characteristics and demographics,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shebley, Mohamad, Polepally, Akshanth R., Nader, Ahmed, Ng, Juki W., Winzenborg, Insa, Klein, Cheri E., Noertersheuser, Peter, Gibbs, Megan A., Mostafa, Nael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051932/ https://www.ncbi.nlm.nih.gov/pubmed/31749075 http://dx.doi.org/10.1007/s40262-019-00840-7

Ejemplares similares

Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
por: Stodtmann, Sven, et al.
Publicado: (2021)

Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model
por: Winzenborg, Insa, et al.
Publicado: (2020)

Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
por: Abbas Suleiman, Ahmed, et al.
Publicado: (2020)

Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist
por: Polepally, Akshanth R., et al.
Publicado: (2020)

Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids
por: Beck, Denise, et al.
Publicado: (2021)

Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids
por: Beck, Denise, et al.
Publicado: (2022)

Effects of elagolix on the pharmacokinetics of omeprazole and its metabolites in healthy premenopausal women
por: Nader, Ahmed, et al.
Publicado: (2022)

Quantitative Assessment of Elagolix Enzyme-Transporter Interplay and Drug–Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
por: Chiney, Manoj S., et al.
Publicado: (2019)

Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women
por: Beck, Denise, et al.
Publicado: (2021)

Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
por: Chwalisz, Kristof
Publicado: (2023)

Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
por: Snabes, Michael C., et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women
por: Feldman, Robert A., et al.
Publicado: (2021)

A Personalized Medicine Approach Using Clinical Utility Index and Exposure‐Response Modeling Informed by Patient Preferences Data
por: Winzenborg, Insa, et al.
Publicado: (2020)

Elagolix: a promising oral GnRH antagonist for endometriosis-associated pain
por: Dun, Erica C., et al.
Publicado: (2017)

A Clinician's Guide to the Treatment of Endometriosis with Elagolix
por: Leyland, Nicholas, et al.
Publicado: (2021)

Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
por: Carr, Bruce, et al.
Publicado: (2013)

Elagolix in the treatment of endometriosis: impact beyond pain symptoms
por: Archer, David F., et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure
por: Mukherjee, Dwaipayan, et al.
Publicado: (2022)

Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix
por: Taylor, Hugh S., et al.
Publicado: (2020)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix
por: Agarwal, Sanjay K, et al.
Publicado: (2021)

Gonadotropin-Releasing Hormone Antagonists—A New Hope in Endometriosis Treatment?
por: Rzewuska, Anna Maria, et al.
Publicado: (2023)

Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Correction to: Elagolix: First Global Approval
por: Lamb, Yvette N.
Publicado: (2018)

Real-World Characterization of Women with Diagnosed Endometriosis Initiating Therapy with Elagolix Using a US Claims Database
por: Surrey, Eric S, et al.
Publicado: (2020)

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis
por: Pohl, Oliver, et al.
Publicado: (2022)

The role of elagolix in the suppression of ovulation in donor oocyte cycles
por: Boniface, Catherine, et al.
Publicado: (2023)

Elagolix: How far can it go in the world of gynecology?
por: Danis, Rachel B.
Publicado: (2023)

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
por: Khatri, Amit, et al.
Publicado: (2019)

Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse
por: Shebley, Mohamad, et al.
Publicado: (2018)

Estimating the Effect of Elagolix Treatment for Endometriosis on Postmenopausal Bone Outcomes: A Model Bridging Phase III Trials to an Older Real‐World Population
por: Kilpatrick, Ryan D, et al.
Publicado: (2020)

Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
por: Abrao, Mauricio S., et al.
Publicado: (2021)

Impact of Elagolix on Workplace and Household Productivity Among Women with Moderate to Severe Pain Associated with Endometriosis: A Pooled Analysis of Two Phase III Trials
por: Surrey, Eric S., et al.
Publicado: (2019)

Does timing matter when initiating elagolix in a natural menstrual cycle?
por: Danis, Rachel B., et al.
Publicado: (2021)

Elagolix is porphyrogenic and may induce porphyric attacks in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis
por: Xin, Lingli, et al.
Publicado: (2023)

Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas
por: Simon, James A., et al.
Publicado: (2020)

Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis
por: Muneyyirci-Delale, Ozgul, et al.
Publicado: (2021)

Elagolix Sodium Salt and Its Synthetic Intermediates: A Spectroscopic, Crystallographic, and Conformational Study
por: Ciceri, Samuele, et al.
Publicado: (2023)

Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cycles
por: Jain, Shikha, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rvhv8k0m6ra9bsobgs4b9jh6nq